• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本全面评估抗菌药物耐药性(AMR)疾病负担之路。

Road to comprehensive estimation of antimicrobial resistance (AMR) disease burden in Japan.

作者信息

Tsuzuki Shinya, Matsunaga Nobuaki, Ohmagari Norio

机构信息

AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.

Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

出版信息

Glob Health Med. 2020 Jun 30;2(3):164-167. doi: 10.35772/ghm.2020.01005.

DOI:10.35772/ghm.2020.01005
PMID:33330801
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7731336/
Abstract

Antimicrobial resistance (AMR) is currently a global health threat. Many countries have issued their own national action plans following the publication of the Global Action Plan on AMR by the World Health Organization. The government of Japan established its own National Action Plan on AMR in 2016; however, Japan's AMR countermeasures are still in the developmental stage. Recently, the AMR Clinical Reference Center (AMR CRC) in Japan estimated the disease burden of AMR in the form of number of deaths attributed to blood-stream infections caused by antimicrobial-resistant organisms. However, a more extensive and precise assessment is needed to understand the disease burden of AMR more clearly and enable us to compare these indicators with those published by other countries. Cassini and colleagues from the World Health Organization estimated the disease burden of AMR in the European Union as disability-adjusted life years (DALYs) in 2018. Their study could be considered an important milestone in terms of its thoroughness. If we hope to estimate the disease burden of AMR in a more precise manner, age-stratified patient data is needed in conjunction with a surveillance report. At present, AMR CRC is attempting to establish such data for examination at the national level - a challenging but worthwhile task.

摘要

抗菌药物耐药性(AMR)目前是一项全球健康威胁。在世界卫生组织发布《抗菌药物耐药性全球行动计划》之后,许多国家都出台了各自的国家行动计划。日本政府于2016年制定了本国的《抗菌药物耐药性国家行动计划》;然而,日本对抗菌药物耐药性的应对措施仍处于发展阶段。最近,日本的抗菌药物耐药性临床参考中心(AMR CRC)以抗菌药物耐药菌引起的血流感染导致的死亡人数形式估算了抗菌药物耐药性的疾病负担。然而,需要进行更广泛、精确的评估,以便更清楚地了解抗菌药物耐药性的疾病负担,并使我们能够将这些指标与其他国家公布的指标进行比较。世界卫生组织的卡西尼及其同事在2018年将欧盟抗菌药物耐药性的疾病负担估算为伤残调整生命年(DALYs)。就其全面性而言,他们的研究可被视为一个重要的里程碑。如果我们希望以更精确的方式估算抗菌药物耐药性的疾病负担,就需要结合监测报告的年龄分层患者数据。目前,AMR CRC正在尝试建立此类数据以便在国家层面进行审查——这是一项具有挑战性但值得去做的任务。

相似文献

1
Road to comprehensive estimation of antimicrobial resistance (AMR) disease burden in Japan.日本全面评估抗菌药物耐药性(AMR)疾病负担之路。
Glob Health Med. 2020 Jun 30;2(3):164-167. doi: 10.35772/ghm.2020.01005.
2
Disease burden of bloodstream infections caused by antimicrobial-resistant bacteria: A population-level study, Japan, 2015-2018.由抗菌药物耐药菌引起的血流感染的疾病负担:2015-2018 年日本的一项基于人群的研究。
Int J Infect Dis. 2021 Jul;108:119-124. doi: 10.1016/j.ijid.2021.05.018. Epub 2021 May 13.
3
Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan.日本抗菌药物消费量下降,且因抗菌药物耐药性导致的疾病负担减轻停滞不前。
Infect Dis Ther. 2023 Jul;12(7):1823-1834. doi: 10.1007/s40121-023-00829-7. Epub 2023 Jun 15.
4
Outcomes and Future Prospect of Japan's National Action Plan on Antimicrobial Resistance (2016-2020).日本《抗菌药物耐药性国家行动计划(2016 - 2020年)》的成果与未来展望
Antibiotics (Basel). 2021 Oct 22;10(11):1293. doi: 10.3390/antibiotics10111293.
5
Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan.估算在日本降低对三种革兰氏阴性病原菌耐药性的经济和临床价值。
J Health Econ Outcomes Res. 2021 Oct 6;8(2):64-75. doi: 10.36469/001c.28327. eCollection 2021.
6
Assessing transparency and accountability of national action plans on antimicrobial resistance in 15 African countries.评估 15 个非洲国家的国家抗微生物药物耐药性行动计划的透明度和问责制。
Antimicrob Resist Infect Control. 2022 Jan 24;11(1):15. doi: 10.1186/s13756-021-01040-4.
7
Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia.澳大利亚抗菌药物耐药感染的疾病负担、相关死亡率及经济影响。
Lancet Reg Health West Pac. 2022 Jul 7;27:100521. doi: 10.1016/j.lanwpc.2022.100521. eCollection 2022 Oct.
8
Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?撒哈拉以南非洲地区的抗菌药物耐药率及监测:我们目前的状况如何?
Infect Drug Resist. 2022 Jul 7;15:3589-3609. doi: 10.2147/IDR.S342753. eCollection 2022.
9
Clinical and Economic Value of Reducing Antimicrobial Resistance in the Management of Hospital-Acquired Infections with Limited Treatment Options in Greece.在希腊治疗选择有限的医院获得性感染管理中降低抗菌药物耐药性的临床和经济价值
Infect Dis Ther. 2023 Jul;12(7):1891-1905. doi: 10.1007/s40121-023-00837-7. Epub 2023 Jul 6.
10
The role of whole genome sequencing in monitoring antimicrobial resistance: A biosafety and public health priority in the Arabian Peninsula.全基因组测序在监测抗生素耐药性中的作用:阿拉伯半岛的生物安全和公共卫生优先事项。
J Infect Public Health. 2018 Nov-Dec;11(6):784-787. doi: 10.1016/j.jiph.2018.08.001. Epub 2018 Aug 9.

引用本文的文献

1
Surveillance of Antimicrobial Prescriptions in Community Pharmacies Located in Tokyo, Japan.日本东京社区药房抗菌药物处方监测
Antibiotics (Basel). 2023 Aug 17;12(8):1325. doi: 10.3390/antibiotics12081325.
2
Occurrence and Quantitative Microbial Risk Assessment of Methicillin-Resistant (MRSA) in a Sub-Catchment of the Yodo River Basin, Japan.日本淀川河流域一个子流域耐甲氧西林金黄色葡萄球菌(MRSA)的发生情况及定量微生物风险评估
Antibiotics (Basel). 2022 Oct 5;11(10):1355. doi: 10.3390/antibiotics11101355.

本文引用的文献

1
National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan.日本金黄色葡萄球菌和大肠杆菌引起的血流感染归因死亡的全国趋势。
J Infect Chemother. 2020 Apr;26(4):367-371. doi: 10.1016/j.jiac.2019.10.017. Epub 2019 Dec 1.
2
Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.健康状态效用值在成本效果模型中的识别、评价和应用:ISPOR 疗效研究实践报告
Value Health. 2019 Mar;22(3):267-275. doi: 10.1016/j.jval.2019.01.004.
3
Correlates of laboratory-confirmed measles in Japan, 2011-2015.日本 2011-2015 年实验室确诊麻疹的相关因素。
Vaccine. 2019 Mar 22;37(13):1756-1762. doi: 10.1016/j.vaccine.2019.02.011. Epub 2019 Feb 22.
4
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.2015 年欧盟及欧洲经济区因抗生素耐药菌感染导致的死亡人数和伤残调整生命年:基于人群的模型分析。
Lancet Infect Dis. 2019 Jan;19(1):56-66. doi: 10.1016/S1473-3099(18)30605-4. Epub 2018 Nov 5.
5
Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013.传染病对人口健康的影响,使用基于发病率的伤残调整生命年(DALYs):2009 至 2013 年欧洲传染病负担研究、欧盟和欧洲经济区国家的结果。
Euro Surveill. 2018 Apr;23(16). doi: 10.2807/1560-7917.ES.2018.23.16.17-00454.
6
Unique characteristics of community-onset healthcare- associated bloodstream infections: a multi-centre prospective surveillance study of bloodstream infections in Japan.社区获得性医疗保健相关血流感染的独特特征:日本血流感染的多中心前瞻性监测研究
J Hosp Infect. 2017 May;96(1):29-34. doi: 10.1016/j.jhin.2017.02.022. Epub 2017 Feb 27.
7
Medical Big Data for Research Use: Current Status and Related Issues.用于研究的医学大数据:现状与相关问题
Japan Med Assoc J. 2016 Sep 1;59(2-3):110-124. eCollection 2016 Sep.
8
A Software Tool for Estimation of Burden of Infectious Diseases in Europe Using Incidence-Based Disability Adjusted Life Years.一种使用基于发病率的伤残调整生命年估算欧洲传染病负担的软件工具。
PLoS One. 2017 Jan 20;12(1):e0170662. doi: 10.1371/journal.pone.0170662. eCollection 2017.
9
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.健康经济评估报告标准(CHEERS)——解释与说明:国际卫生经济学会健康经济评估报告指南良好报告实践工作组报告。
Value Health. 2013 Mar-Apr;16(2):231-50. doi: 10.1016/j.jval.2013.02.002.
10
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.291 种疾病和伤害导致的伤残调整生命年(DALYs)在 21 个地区,1990-2010 年:全球疾病负担研究 2010 的系统分析。
Lancet. 2012 Dec 15;380(9859):2197-223. doi: 10.1016/S0140-6736(12)61689-4.